Literature DB >> 24924549

The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2.

T C Booth1, M Nathan2, A D Waldman3, A-M Quigley2, A H Schapira4, J Buscombe5.   

Abstract

SUMMARY: The functional imaging technique most widely used in European clinics to differentiate a true parkinsonian syndrome from vascular parkinsonism, drug-induced changes, or essential tremor is dopamine-transporter SPECT. This technique commonly reports dopamine-transporter function, with decreasing striatal uptake demonstrating increasingly severe disease. The strength of dopamine-transporter SPECT is that nigrostriatal degeneration is observed in both clinically inconclusive parkinsonism and early, even premotor, disease. In this clinical review (Part 2), we present the dopamine-transporter SPECT findings in a variety of neurodegenerative diseases, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. The findings in vascular parkinsonism, drug-induced parkinsonism, and essential tremor are also described. It is hoped that this technique will be the forerunner of a range of routinely used, process-specific ligands that can identify early degenerative disease and subsequently guide disease-modifying interventions.
© 2015 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24924549      PMCID: PMC7965658          DOI: 10.3174/ajnr.A3971

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  65 in total

1.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

Authors:  T S Benamer; J Patterson; D G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H Horstink; H J Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

2.  Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.

Authors:  J B Schulz; M Skalej; D Wedekind; A R Luft; M Abele; K Voigt; J Dichgans; T Klockgether
Journal:  Ann Neurol       Date:  1999-01       Impact factor: 10.422

3.  Differentiation of atypical parkinsonian syndromes with routine MRI.

Authors:  A Schrag; C D Good; K Miszkiel; H R Morris; C J Mathias; A J Lees; N P Quinn
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

4.  Medial temporal lobe atrophy on MRI in dementia with Lewy bodies.

Authors:  R Barber; A Gholkar; P Scheltens; C Ballard; I G McKeith; J T O'Brien
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

5.  In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.

Authors:  D C Costa; N P Verhoeff; I D Cullum; P J Ell; G M Syed; J Barrett; E Palazidou; B Toone; E Van Royen; M Bobeldijk
Journal:  Eur J Nucl Med       Date:  1990

6.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack
Journal:  Brain       Date:  2007-01-31       Impact factor: 13.501

7.  123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia.

Authors:  Hans Sjøholm; Trond Bratlid; Johan Sundsfjord
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

8.  Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy.

Authors:  C Brenneis; K Seppi; M Schocke; T Benke; G K Wenning; W Poewe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

9.  Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration.

Authors:  A Erbetta; M L Mandelli; M Savoiardo; M Grisoli; A Bizzi; P Soliveri; L Chiapparini; S Prioni; M G Bruzzone; F Girotti
Journal:  AJNR Am J Neuroradiol       Date:  2009-07-09       Impact factor: 3.825

10.  Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease.

Authors:  Michael J Firbank; Andrew M Blamire; Mani S Krishnan; Andrew Teodorczuk; Philip English; Anil Gholkar; Roger M Harrison; John T O'Brien
Journal:  Psychiatry Res       Date:  2007-04-03       Impact factor: 3.222

View more
  14 in total

1.  The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al.

Authors:  Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard
Journal:  Neurol Sci       Date:  2017-06-01       Impact factor: 3.307

Review 2.  Neurophysiology and neurochemistry of corticobasal syndrome.

Authors:  Aditya A Murgai; Mandar S Jog
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

3.  Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson's disease.

Authors:  Takuro Shiiba; Kazuki Takano; Akihiro Takaki; Shugo Suwazono
Journal:  EJNMMI Res       Date:  2022-06-27       Impact factor: 3.434

Review 4.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

5.  Comparison of MRI and 123I-FP-CIT SPECT for the evaluation of MSA-P clinical severity.

Authors:  Miki Nishimori; Yoriko Murata; Hitomi Iwasa; Kana Miyatake; Michiko Tadokoro; Shino Kohsaki; Munenobu Nogami; Norihiko Hamada; Hitoshi Ninomiya; Yasushi Osaki; Hirokazu Furuya; Takuji Yamagami
Journal:  Biomed Rep       Date:  2018-04-11

6.  Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan).

Authors:  Yuichi Wakabayashi; Ryuichi Takahashi; Tomonori Kanda; Feibi Zeng; Munenobu Nogami; Kazunari Ishii; Takamichi Murakami
Journal:  Neurol Sci       Date:  2018-05-10       Impact factor: 3.307

7.  Single-site 123I-FP-CIT reference values from individuals with non-degenerative parkinsonism-comparison with values from healthy volunteers.

Authors:  Rachid Fahmi; Günther Platsch; Alexandre Bani Sadr; Sylvain Gouttard; Stephane Thobois; Sven Zuehlsdorff; Christian Scheiber
Journal:  Eur J Hybrid Imaging       Date:  2020-03-13

8.  Imaging analysis of Parkinson's disease patients using SPECT and tractography.

Authors:  Seong-Jin Son; Mansu Kim; Hyunjin Park
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

9.  Oral phase dysphagia in facial onset sensory and motor neuronopathy.

Authors:  Mitsuru Watanabe; Wataru Shiraishi; Ryo Yamasaki; Noriko Isobe; Motohiro Sawatsubashi; Ryuji Yasumatsu; Takashi Nakagawa; Jun-Ichi Kira
Journal:  Brain Behav       Date:  2018-05-21       Impact factor: 2.708

10.  Reduced 123I Ioflupane Binding in Bilateral Diabetic Chorea: Findings With 18F FDG PET, 99mTc ECD SPECT, and 123I MIBG Scintigraphy.

Authors:  Kenichiro Sato; Ayumi Hida; Masashi Kameyama; Miyako Morooka; Sousuke Takeuchi
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.